OverviewSuggest Edit

Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. The company’s aim is a commercial-stage biopharmaceutical company in the area of immunotherapy and focuses on the research in medical needs in cancer.

TypePublic
Founded1999
HQMarseille, FR
Websiteinnate-pharma.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2020)244(+4%)
Job Openings5
Revenue (FY, 2020)€70.5 M(-17%)
Share Price (Nov 2021)€4.6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Innate Pharma

Herve Brailly

Herve Brailly

Chairman of the Supervisory Board, Co-founder
Odile Laurent

Odile Laurent

Vice President, Human Resources Director
Irina Staatz-Granzer

Irina Staatz-Granzer

Vice-Chairman
Mondher Mahjoubi

Mondher Mahjoubi

Chairman of the Executive Board and Chief Executive Officer
Maïlys Ferrere

Maïlys Ferrere

Board Member
Laure-Hélène Mercier

Laure-Hélène Mercier

Executive Vice President, Chief Financial Officer and Member of the Executive Board
Show more

Innate Pharma Office Locations

Innate Pharma has offices in Marseille and Rockville
Marseille, FR (HQ)
117 Avenue de Luminy
Rockville, MD, US
2273 Research Blvd #350
Show all (2)

Innate Pharma Financials and Metrics

Innate Pharma Revenue

Innate Pharma's revenue was reported to be €70.45 m in FY, 2020
EUR

Revenue (FY, 2020)

70.5m

Net income (FY, 2020)

(64.0m)

EBIT (FY, 2020)

(62.1m)

Market capitalization (10-Nov-2021)

362.4m

Closing stock price (10-Nov-2021)

4.6

Cash (31-Dec-2020)

136.8m
Innate Pharma's current market capitalization is €362.4 m.
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

44.0m94.0m85.8m70.5m

Revenue growth, %

113%

Sales and marketing expense

516.0k

General and administrative expense

17.0m18.1m31.2m
Half Year
EURH1, 2018H1, 2019

Revenue

23.0m59.2m

General and administrative expense

5.6m9.3m

R&D expense

32.3m36.6m

Operating expense total

37.9m45.9m
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

99.4m152.3m202.9m136.8m

Accounts Receivable

2.5m10.6m

Current Assets

137.5m319.6m237.6m173.5m

PP&E

10.7m10.2m11.7m11.7m
Quarterly
EURQ2, 2019

Cash

149.4m

Accounts Receivable

5.5m

Current Assets

216.7m

PP&E

11.4m
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(48.4m)3.0m(20.8m)(64.0m)

Depreciation and Amortization

4.4m7.4m16.5m56.8m

Cash From Operating Activities

(48.1m)(32.5m)34.9m(51.8m)

Purchases of PP&E

(3.0m)(873.0k)
Quarterly
EURQ2, 2018Q2, 2019

Net Income

(15.1m)13.2m

Depreciation and Amortization

2.4m6.8m

Cash From Operating Activities

(33.9m)59.6m

Purchases of PP&E

(709.0k)(738.0k)
EURFY, 2017

EV/EBIT

-10.3 x

EV/CFO

-8.6 x

Revenue/Employee

234.2k

Debt/Equity

0.1 x

Financial Leverage

3 x
Show all financial metrics

Innate Pharma Operating Metrics

Q2, 2019

Phase I Trials Products

3

Phase II Trials Products

5

Pre-Clinical Phase Products

7
Show all operating metrics

Innate Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Innate Pharma France SAS
Innate Pharma Inc

Innate Pharma Revenue Breakdown

Embed Graph

Innate Pharma revenue breakdown by business segment: 15.0% from Government financing for research expenditures and 85.0% from Revenue from collaboration and licensing agreements

Innate Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Innate Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Innate Pharma Online and Social Media Presence

Embed Graph

Innate Pharma News and Updates

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“In…

Thinking about buying stock in Innate Pharma, Beachbody Company, Gritstone bio, Enveric Biosciences, or Lucid Group?

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IPHA, BODY, GRTS, ENVB, and LCID. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Innate Pharma reports first half 2021 financial results and business update

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release.

Innate Pharma Reports First Half 2021 Financial Results and Business Update

MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release.

Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update

MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress…

Thinking about buying stock in Innate Pharma, Biotricity, Nutanix, Celsion Corp, or Globalstar?

NEW YORK, Sept. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IPHA, BTCY, NTNX, CLSN, and GSAT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Innate Pharma Blogs

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer

CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer cvoisin Wed, 11/24/2021 - 18:57 Authors Magagna Date 1 day 8 hours ago Lin…

Innate Pharma to participate in the Evercore ISI 4th Annual Healthconx Virtual Conference

Innate Pharma to participate in the Evercore ISI 4th Annual Healthconx Virtual Conference Wed, 11/24/2021 - 07:00 Press Release in English 140.63 KB …

Innate Pharma Third Quarter 2021 Report

Innate Pharma Third Quarter 2021 Report Tue, 11/16/2021 - 07:00 Press Release in English 337.03 KB Communiqu…

Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting

Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC annual meeting Fri, 11/12/2021 - 13:00 Press Release in English 245.47 KB …

Innate Pharma announces Conference Call and Webcast for Q3 2021 Business Update

Innate Pharma announces Conference Call and Webcast for Q3 2021 Business Update Tue, 11/09/2021 - 07:00 Press Release in English 130.64 KB …

Number of shares and voting rights of Innate Pharma as of October 1, 2021

Number of shares and voting rights of Innate Pharma as of October 1, 2021 Fri, 10/15/2021 - 07:00 Press Release in English 170.62 KB …
Show more

Innate Pharma Frequently Asked Questions

  • When was Innate Pharma founded?

    Innate Pharma was founded in 1999.

  • Who are Innate Pharma key executives?

    Innate Pharma's key executives are Herve Brailly, Odile Laurent and Irina Staatz-Granzer.

  • How many employees does Innate Pharma have?

    Innate Pharma has 244 employees.

  • What is Innate Pharma revenue?

    Latest Innate Pharma annual revenue is €70.5 m.

  • What is Innate Pharma revenue per employee?

    Latest Innate Pharma revenue per employee is €288.7 k.

  • Who are Innate Pharma competitors?

    Competitors of Innate Pharma include Ablynx, Micronoma and Cartherics.

  • Where is Innate Pharma headquarters?

    Innate Pharma headquarters is located at 117 Avenue de Luminy, Marseille.

  • Where are Innate Pharma offices?

    Innate Pharma has offices in Marseille and Rockville.

  • How many offices does Innate Pharma have?

    Innate Pharma has 2 offices.